View Older Stories View More Recent Stories

Jan 21, 2016 01:05AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jan 18, 2016 01:19AM PERCEPTIVE ADVISORS LLC ANNOUNCE 5.06% SHAREHOLDING IN ABLYNX
Jan 7, 2016 01:04AM ABLYNX TO PRESENT AT THE 34th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Jan 5, 2016 01:07AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Dec 22, 2015 01:10AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Dec 17, 2015 01:05AM ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS
Dec 16, 2015 12:13PM ABLYNX ANNOUNCES WARRANT EXERCISE
Dec 9, 2015 01:07AM ABLYNX ANNOUNCES WARRANT EXERCISE
Dec 2, 2015 01:04AM JP MORGAN ASSET MANAGEMENT HOLDINGS ANNOUNCE 3.33% SHAREHOLDING IN ABLYNX
Dec 1, 2015 01:05AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Nov 30, 2015 01:14AM ABLYNX APPOINTS ROBERT K. ZELDIN, MD, CHIEF MEDICAL OFFICER
Nov 25, 2015 01:06AM ABLYNX ANNOUNCES NANOBODY DRUG DISCOVERY COLLABORATION WITH NOVO NORDISK
Nov 18, 2015 01:08AM ABLYNX PROVIDES BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2015
Nov 5, 2015 01:05AM ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EURO GLOBAL SUMMIT ON CANCER THERAPY
Oct 21, 2015 01:08AM ABLYNX ANNOUNCES WARRANT EXERCISE
Oct 15, 2015 01:09AM ABLYNX ACHIEVES FIRST MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.
Sep 29, 2015 01:04AM ABLYNX INITIATES A MULTINATIONAL PHASE III STUDY WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP, A RARE BLOOD CLOTTING DISORDER
Aug 27, 2015 01:06AM ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015
Aug 19, 2015 01:04AM ABLYNX TO HOST WEBCAST FOR ITS 2015 HALF-YEAR RESULTS ON 27 AUGUST
Aug 14, 2015 01:10AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Aug 4, 2015 01:06AM ABLYNX INITIATES PHASE II SLE STUDY WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE
Jul 31, 2015 01:05AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 29, 2015 01:05AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jul 22, 2015 01:08AM ABLYNX SIGNIFICANTLY EXPANDS ITS IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.
Jul 20, 2015 01:04AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 14, 2015 01:11AM OPPENHEIMER FUNDS, INC. ANNOUNCE 3.07% SHAREHOLDING IN ABLYNX
Jul 1, 2015 01:07AM TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 5.14% SHAREHOLDING IN ABLYNX
Jun 30, 2015 02:07AM ABLYNX AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ANTI-TNFa NANOBODY (OZORALIZUMAB) IN JAPAN
May 13, 2015 01:09AM ABLYNX ANNOUNCES BUSINESS UPDATE AND FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2015
Apr 15, 2015 01:08AM FMR LLC PROVIDE NOTIFICATION OF SHAREHOLDING IN ABLYNX
Apr 7, 2015 12:07PM ABLYNX ANNOUNCES PUBLICATION OF 2014 ANNUAL REPORT AND LAUNCH OF NEW WEBSITE
Apr 7, 2015 01:05AM ABLYNX INITIATES THE SECOND OF TWO PHASE IIb RA STUDIES WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE
Mar 26, 2015 02:09AM ABLYNX ANNOUNCES EXTENSION OF ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC.
Mar 17, 2015 02:08AM ABLYNX INITIATES THE FIRST OF TWO PHASE IIb RA STUDIES WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE
Mar 16, 2015 01:13PM ABLYNX ANNOUNCES WARRANT EXERCISE
Mar 16, 2015 02:03AM POLAR CAPITAL FUNDS PLC AND FMR LLC PROVIDE NOTIFICATION OF SHAREHOLDING IN ABLYNX
View More Recent Stories View Older Stories